Progression patterns and site-specific responses in advanced gastric cancer patients treated with nivolumab.

ABSTRACT:

Background

While the efficacy of immune checkpoint inhibitors (ICIs) reportedly varies among metastatic sites and progression patterns (classified as systemic progression [SP] or mixed progression [MP]), the clinical efficacy of ICIs against gastric cancer remains unclear. The response to nivolumab depending on metastatic site and clinical outcomes according to progression pattern in patients with advanced gastric cancer was investigated retrospectively.

Methods

Seventy-four advanced gastric cancer patients with measurable lesions who received nivolumab monotherapy between 2015 and 2020 were enrolled. Progression-free survival (PFS), overall survival, response at each metastatic site, and clinical outcomes according to progression pattern were analyzed retrospectively. SP an

SUBMITTER: Kadono T 

PROVIDER: S-EPMC10166927 | biostudies-literature | 2023 Apr

REPOSITORIES: biostudies-literature